{{Rsnum
|rsid=4775936
|Gene=CYP19A1
|Chromosome=15
|position=51243825
|Orientation=plus
|GMAF=0.3393
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=CYP19A1
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 25.7 | 42.5 | 31.9
| HCB | 35.0 | 45.3 | 19.7
| JPT | 39.8 | 43.4 | 16.8
| YRI | 87.1 | 12.2 | 0.7
| ASW | 78.9 | 19.3 | 1.8
| CHB | 35.0 | 45.3 | 19.7
| CHD | 31.2 | 47.7 | 21.1
| GIH | 41.6 | 44.6 | 13.9
| LWK | 83.6 | 14.5 | 1.8
| MEX | 44.8 | 48.3 | 6.9
| MKK | 60.3 | 35.3 | 4.5
| TSI | 40.2 | 40.2 | 19.6
| HapMapRevision=28
}}{{PMID|19064562|OA=1
}} increased risk of [[breast cancer]] with concurrent proliferative fibrocystic conditions
*[[rs1004982]](C) 2.19 (1.24-3.85)
*[[rs28566535]](C) 2.20 (1.27-3.82)
*[[rs936306]](T) 1.94 (1.13-3.30) 
*[[rs4775936]](C) 1.95 (1.07-3.58)

{{omim
|desc=CYTOCHROME P450, FAMILY 19, SUBFAMILY A, POLYPEPTIDE 1; CYP19A1
|id=107910
|rsnum=4775936
}}

{{PMID Auto
|PMID=21442439
|Title=Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer
}}

{{PMID Auto
|PMID=22418701
|Title=Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients
}}

{{PMID|16344016}} A new SNP in a negative regulatory region of the CYP19A1 gene is associated with lumbar spine BMD in postmenopausal women.

{{PMID|17903296|OA=1
}} Genome-wide association with bone mass and geometry in the Framingham Heart Study.

{{PMID|18636124|OA=1
}} Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma.

{{PMID|19150398|OA=1
}} Quantitative trait loci, genes, and polymorphisms that regulate bone mineral density in mouse.

{{PMID Auto
|PMID=22633539
|Title=Selected polymorphisms in sex hormone-related genes, circulating sex hormones and risk of endometrial cancer.
|OA=1
}}

{{PMID Auto
|PMID=23408108
|Title=Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy.
|OA=1
}}

{{PMID Auto
|PMID=24803183
|Title=Effects of functional genetic polymorphisms in the CYP19A1 gene on prostate cancer risk and survival
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | Illumina Human 1M}}